# J B Chemicals & Pharmaceuticals share price (J B Chemicals & Pharmaceuticals Ltd, NSE: JBCHEPHARM) > J B Chemicals & Pharmaceuticals share price: ₹2,408.90 at the NSE close on 16 July 2026, the latest close in our records; up 45.6% in the year to that date. J B Chemicals & Pharmaceuticals (NSE: JBCHEPHARM) is worth ₹38,677 crore, trades at a P/E of 53.3 and has closed between ₹1,654.10 and ₹2,435.50 over the past 52 weeks. > J B Chemicals & Pharmaceuticals Ltd's share price has risen faster than its earnings: +45.6% in a year, against +4.3% for earnings per share. JBCHEPHARM · Pharma - Formulators · data as of 16 July 2026. Page: https://www.sectoralpha.in/stocks/j-b-chemicals-pharmaceuticals-ltd Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms ## Key numbers - Business trend: Growing steadily, from the last 12 quarters - Price: ₹2,408.90 (+45.6% in a year) - P/E: 53.3× (higher than 98% of the last 10 years) - Revenue (Mar 2026): ₹904 Cr (−4.7% on a year ago) - Profit (Mar 2026): ₹101 Cr (−30.8% on a year ago) - Operating margin: 22.2% (−1.6 points on a year ago) - ROCE: 25%, FY26 - ROIC: 22.2%, against a 12.0% cost of capital: +10.2 points The main question: the share price moved +45.6% in a year while yearly earnings per share moved +4.3%. The difference came from the market paying a higher multiple. ## What is the J B Chemicals & Pharmaceuticals share price? J B Chemicals & Pharmaceuticals Ltd's share price was ₹2,408.90 at the close on 16 July 2026. It has been rising for 34 weeks. That is 18.9% above its average price over the last 200 trading days. In the last 52 weeks it traded between ₹1,654 and ₹2,436, and at that close it sat 97% of the way up from that low. Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 9 weeks in a row. Over the last 10 years the share price moved +1,854% while the NIFTY 500 moved +299%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What changed at J B Chemicals & Pharmaceuticals this quarter? Two changes stood out: profit fell in the March 2026 quarter and lowest operating margin in 12 quarters. 1. Profit fell in the March 2026 quarter Profit was ₹101 crore, -30.8% on a year earlier (₹146 crore), after 9 quarters of growth. Why: Profit fell because international sales dropped in the March quarter as shipments were held up by container congestion and inventory cuts. Next results: check CDMO sales in the June quarter, since management said the problem is delivery execution, not customers or capacity. From the earnings call on 12 May 2026. 2. Lowest operating margin in 12 quarters Operating margin was 22% in the March 2026 quarter, against 24% a year earlier. ## What are J B Chemicals & Pharmaceuticals' latest quarterly results? For January to March 2026 (the quarter ended 31 March 2026), J B Chemicals & Pharmaceuticals reported revenue of ₹904 crore, down 4.7% from ₹949 crore a year earlier, and a profit of ₹101 crore, down 30.8% from ₹146 crore. ### J B Chemicals & Pharmaceuticals results: January to March 2026 against a year earlier | Measure | January to March 2026 | January to March 2025 | Change | | --- | --- | --- | --- | | Revenue | ₹904 crore | ₹949 crore | −4.7% | | Profit | ₹101 crore | ₹146 crore | −30.8% | | Earnings per share | ₹6.31 | ₹9.36 | −32.6% | | Operating margin | 22.2% | 23.8% | −1.6 points | The next results, for April to June 2026, are due by 14 August 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). J B Chemicals & Pharmaceuticals' management discussed these results on a call held on 12 May 2026; what it said is further down this page. (From the company's reported quarterly results (quarter ended 31 March 2026). Revenue and profit in ₹ crore.) ## What is the J B Chemicals & Pharmaceuticals share price history? J B Chemicals & Pharmaceuticals closed at ₹2,408.90 on 16 July 2026, up 45.6% from ₹1,654.10 a year earlier (18 July 2025) and up 154.6% over five years. Its highest weekly close since February 2016 was ₹2,435.50 on 10 July 2026. ### J B Chemicals & Pharmaceuticals share price: then and now | When | Close | Change to 16 Jul 2026 | | --- | --- | --- | | 1 week ago · 10 Jul 2026 | ₹2,435.50 | −1.1% | | 1 month ago · 17 Jun 2026 | ₹2,195.60 | +9.7% | | 6 months ago · 16 Jan 2026 | ₹1,904.00 | +26.5% | | 1 year ago · 18 Jul 2025 | ₹1,654.10 | +45.6% | | 3 years ago · 14 Jul 2023 | ₹1,284.53 | +87.5% | | 5 years ago · 16 Jul 2021 | ₹946.10 | +154.6% | | 10 years ago · 15 Jul 2016 | ₹131.25 | +1,735.4% | | Earliest weekly close in our records · 26 Feb 2016 | ₹123.28 | +1,854.0% | | Highest weekly close since February 2016, also the 52-week high · 10 Jul 2026 | ₹2,435.50 | −1.1% | | Lowest weekly close since February 2016 · 24 Jun 2016 | ₹117.93 | +1,942.7% | | 52-week low (weekly close) · 18 Jul 2025 | ₹1,654.10 | +45.6% | Weekly closing prices, adjusted for splits and bonuses so every price is on today’s share count. Each change is the move from that price to the 16 Jul 2026 close. A day's intraday high or low can go beyond these weekly closes. (549 weekly closes from 26 February 2016 to 16 July 2026.) ## What is the latest news on J B Chemicals & Pharmaceuticals? 16 Jul 2026: J B Chemicals & Pharmaceuticals closed at ₹2,408.90, down 1.1% on the week and up 9.7% on the month. 29 May 2026: ex-date for a dividend of ₹9.30 a share. ### Earlier - Our read, 17 May 2026: A chronic-mix compounder hit by a Torrent-integration reset, the branded core is intact, but CDMO missed by 12-14pp and management guidance credibility is impaired. - 12 May 2026: J B Chemicals & Pharmaceuticals held its results call for January to March 2026. Management guided: India branded business return to double-digit or low-teens growth within couple of quarters. - Results for January to March 2026: Revenue down 4.7% and profit down 30.8% on a year earlier. - 11 Feb 2026: ex-date for an interim dividend of ₹12.70 a share. ### Our read of the business India branded grew 11% vs 10% IPM in FY26; chronic segment +19% vs industry +14%; 400 basis points gross margin expansion in Q4 to 70% from trade-generics exit, the underlying franchise is healthy. January to March 2026: Integration reset complete; CDMO misses again by 12-14pp. (Our read after the January to March 2026 results, written 17 May 2026.) ## What dividend does J B Chemicals & Pharmaceuticals pay? J B Chemicals & Pharmaceuticals paid ₹22 a share in regular dividends in the 12 months to 18 November 2026 (2 payments), a yield of 0.91% at the ₹2,408.90 close on 16 July 2026. The last was a dividend of ₹9.30 a share, ex-date 29 May 2026. ### J B Chemicals & Pharmaceuticals dividends since 1 April 2021 | Ex-date | Dividend per share | Type | Record date | | --- | --- | --- | --- | | 29 May 2026 | ₹9.30 | Dividend | same day | | 11 Feb 2026 | ₹12.70 | Interim | same day | | 30 Jul 2025 | ₹7 | Dividend | same day | | 7 Feb 2025 | ₹8.50 | Interim | 8 Feb 2025 | | 14 Aug 2024 | ₹6.75 | Dividend | same day | | 16 Feb 2024 | ₹5.50 | Interim | same day | | 17 Aug 2023 | ₹9.25 | Dividend | same day | | 17 Feb 2023 | ₹8.50 | Interim | 18 Feb 2023 | | 12 Aug 2022 | ₹8 | Dividend | 17 Aug 2022 | | 23 Feb 2022 | ₹8.50 | Interim | 24 Feb 2022 | | 1 Sep 2021 | ₹8 | Dividend | 2 Sep 2021 | Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date. 5 of 5 Of the last 5 financial years, years with an NSE dividend record Yes. J B Chemicals & Pharmaceuticals Ltd paid out 50% of its profit as dividends in FY26, and it paid a dividend in each of its last 13 reported years. (From the NSE corporate-actions record, read 18 November 2026.) ## What did J B Chemicals & Pharmaceuticals management say on the latest results call? On the call for January to March 2026, held on 12 May 2026, J B Chemicals & Pharmaceuticals' management guided: India branded business return to double-digit or low-teens growth within couple of quarters. > “For the India business, double-digit growth or low-teens growth would take maybe a couple of quarters. We are already seeing all the positive signs.” > Aman Mehta, MD, on the call for January to March 2026 ### What management guided - International formulations single-digit growth trajectory expected from July to September 2026 onwards. - CDMO business positive momentum on 12-month basis achievable if execution improves. - Gross margin guidance deferred to April to June 2026 results for normalized run-rate clarity on cleaner trade-generics-free portfolio. - Merger completion expected 1-2 months post second week June hearing. Management’s own plans and goals, from our notes of the call. A plan is not a result. Source: [the call transcript](https://files.tijorifinance.com/insight/india/909/Conference Call/CC-May26.pdf). (From the call for January to March 2026, 12 May 2026.) ## What is the future of J B Chemicals & Pharmaceuticals? What is changing in the business? What is changing at J B Chemicals & Pharmaceuticals, from the latest results and calls: chronic portfolio mix shift, structural gross margin expansion, india market share gains, outperforming ipm consistently and torrent merger integration synergies. - Chronic Portfolio Mix Shift, Structural Gross Margin Expansion. Chronic segment grew 19% vs industry 14% in FY26; trade-generics exit (7-8% of India sales) drove 400 basis points gross margin expansion to 70% in Q4, structural improvement, not seasonal. ⚠ estimate - India Market Share Gains, Outperforming IPM Consistently. Fastest growing among top-25 IPM companies; 300-400 basis points volume growth advantage; 6 brands now in top-300 IPM. ⚠ estimate - Torrent Merger Integration Synergies. Procurement synergies visible since April 2026; distribution network optimization underway; back-end consolidation and coverage expansion for chronic therapies expected post-merger completion. ⚠ estimate - CDMO Business Recovery (Execution-Dependent). CDMO flat at ₹494 crore in FY26 vs 12-14% guide; management confirms customers and capacity are adequate, execution acceleration is the only constraint. ⚠ estimate We check 16 kinds of change in every company, such as costs spread over more sales, higher-value products, new orders, new regions or falling debt, against its reported numbers and what management said on its calls. Only changes the numbers back are shown. (Our read after the January to March 2026 results, written 17 May 2026.) ## What could change the J B Chemicals & Pharmaceuticals story? What are the risks? 4 clear guidance misses across 4 calls: CDMO (flat vs 12-14%), domestic (9% vs 12-14%), international (Q4 -9% vs high-single H2 guide), CDMO FY27 run rate abandoned. Risks remain undisclosed until post-fact. ### The main risks - Management Guidance Credibility, Systematic Pattern of Misses: 4 clear guidance misses across 4 calls: CDMO (flat vs 12-14%), domestic (9% vs 12-14%), international (Q4 -9% vs high-single H2 guide), CDMO FY27 run rate abandoned. Risks remain undisclosed until post-fact. ✓ fact - Trade Generics Exit Depresses Reported Growth 3+ Quarters: ~7-8% of India sales (low-margin trade generics) discontinued in Q4; will depress reported India growth by 'a few percent' through January to March 2027 minimum per management. ✓ fact - CDMO Execution Risk, Internal Process Development Bottleneck: CDMO execution delays are internal (team capability gap in process development, not capacity or customer), credibility lowest after missing guidance by 12-14pp in FY26. ✓ fact - International Formulations, West Asia Geopolitical Uncertainty: International formulations down 9% in January to March 2026; container congestion in Middle East/Asia plus inventory rationalization; West Asia crisis timing 'anybody's guess' per management. ✓ fact (Our read after the January to March 2026 results, written 17 May 2026.) ## What to watch in J B Chemicals & Pharmaceuticals' next results? When J B Chemicals & Pharmaceuticals reports April to June 2026, these are the 4 checks that show whether the story is still on course. First: April to June 2026 India branded business organic growth rate - compare Q4 8% to Q1 results; management guided couple of quarters to double-digit return, so Q1 should inflect higher if operational reset normalizing; slowdown below 5-6% would signal headwinds exceed expectations. Management raised each of these on the latest results call. - April to June 2026 India branded business organic growth rate - compare Q4 8% to Q1 results; management guided couple of quarters to double-digit return, so Q1 should inflect higher if operational reset normalizing; slowdown below 5-6% would signal headwinds exceed expectations. - Gross margin normalized run-rate guidance in Q1 results - management explicitly deferring FY27 full-year margin guidance to Q1 pending clean portfolio clarity; watch for steady-state operating margin indicating where trade-generics-free business settles and validating synergy assumptions. - Merger completion announcement and post-close roadmap - hearing second week June with expected 1-2 month completion window; watch for announcement timing, first quantified synergy goals, and field force deployment plan for chronic product coverage expansion priority. - CDMO Q1 revenue trajectory and development pipeline evidence - management identified execution not capacity as constraint; watch for Q1 new product launches from top five customers (P&G, Kenvue, Abnova, Reckitt) indicating execution acceleration delivering results. ## Which stock lists is J B Chemicals & Pharmaceuticals on? J B Chemicals & Pharmaceuticals is on 2 of our India lists: Small & mid cap stocks and Pharma stocks. - [Small & mid cap stocks Size rank in India: 237](https://www.sectoralpha.in/small-cap-stocks-india) - [Pharma stocks Market value: ₹38,677 crore](https://www.sectoralpha.in/sectors/pharma-stocks-india) ## Is J B Chemicals & Pharmaceuticals profitable? J B Chemicals & Pharmaceuticals Ltd earned ₹101 Cr of net profit in the Mar 2026 quarter, −30.8% on the same quarter a year earlier. Full-year FY26 profit was ₹709 Cr. Over 10 years profit has grown 15.8% a year on average. The Mar 2026 quarter's profit is 11.2% of that quarter's revenue. The same quarter a year earlier earned ₹146 Cr. For the full year, FY26 profit was ₹709 Cr (+7.4% on the year before). Why profit moved: revenue changed −4.7% on a year earlier and the margin moved −1.6 percentage points. Sales did the work, and the margin was about flat. On average over the last four quarters, profit changed +6.1% and revenue +5.8%. Profit and revenue are moving at about the same pace. ## How much revenue does J B Chemicals & Pharmaceuticals make, and is it growing? J B Chemicals & Pharmaceuticals Ltd reported ₹904 Cr of revenue in the Mar 2026 quarter, −4.7% on the same quarter a year earlier. Over 10 years it has grown 13.1% a year on average. The last full year, FY26, came in at ₹4,148 Cr. The last four reported quarters add to ₹4,148 Cr. Why this happened. JB Pharma has sustained 200-400 bps outperformance of IPM growth for multiple years. Q1 FY26: 13% vs 9% market (+400bps); Q2 FY26: 12% domestic vs 8% market; Q3 FY26: domestic grew 10% outperforming IPM. Six brands in top-300 IPM, three brands in top-100. Volume growth consistently 4-5% vs IPM 0.3-1%. The merged Torrent entity is expected to add coverage in chronic therapy areas where JB brands have gaps, potentially accelerating share gains. FY26 revenue was ₹4,148 Cr, +5.9% on the year before. Recent pace: the last four quarters grew +5.8% on average, against 13.1% a year over the longer run, so this year is growing slower than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +5.9%, against +9.1% a year over the last 8 quarters (rolling over); profit over the last 12 months grew +7.4%, against +13.2% a year (rolling over). ## How much of every ₹100 of sales does J B Chemicals & Pharmaceuticals keep? J B Chemicals & Pharmaceuticals Ltd's operating margin was 22.2% in the Mar 2026 quarter, 1.6 percentage points lower than the same quarter a year ago. Across 13 years it has been between 14.5% and 27.4%. The latest quarter is within that range. Why this happened. JB Pharma has been systematically pivoting its India business toward higher-margin chronic therapies (cardiology, ophthalmology, CNS) since the Novartis ophthal portfolio acquisition. FY26 India branded grew 11% vs 10% IPM with chronic +19% vs +14% industry. The Q4 discontinuation of the trade-generics business (~7-8% of India sales running at zero margin per Torrent's commentary) eliminated the biggest margin drag, lifting gross margin 400bps to 70%. Key franchises: Rosuvastatin crossed Rs 100 Cr MAT, Sporolac grew from Rs 70 Cr (June 2022) to Rs 146 Cr (June 2025), Azmarda at Rs 75 Cr in cardiology heart failure. The chronic thesis is durable and margin-accretive. Why the margin moved: operating margin changed −1.6 percentage points on the year while gross margin changed +3.5 points. So the drop came mostly from the gross margin, which means input costs and prices charged. ## Is J B Chemicals & Pharmaceuticals' profit turning into cash? Over the last 3 years, 125% of J B Chemicals & Pharmaceuticals Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹704 Cr of operating cash against ₹709 Cr of profit. After ₹83.0 Cr of spending on assets, ₹621 Cr was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why 125% of profit came in as cash: the cash cycle stayed about the same between FY21 and FY26, so the cash follows profit, not the cycle. What to look at next: no single use of cash stands out. The next section checks both the cash tied up in daily operations and the spending on assets. ## Where does J B Chemicals & Pharmaceuticals' cash go? J B Chemicals & Pharmaceuticals Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 151 days in FY26, down from 153 days in FY21. It spent ₹308 Cr on assets over the last 3 years. Customers take 69 days to pay, and stock sits for 192 days on average. At FY26 sales of ₹4,148 Cr, each day of that cycle ties up about ₹11.4 Cr, so roughly ₹1,716 Cr is tied up in the business at any time. FY26: customers took 69 days to pay and stock sat for 192 days, about 6.3 months of sales sitting as stock, for a full cycle of 151 days, shorter than FY21's 153. The full loop: cash goes out to suppliers and production on day 0. Stock sits for 192 days. Customers pay about 69 days after that. Suppliers are paid at 110 days. Together that makes the 151-day cycle. Spending on assets: ₹308 Cr over the last 3 years, against ₹491 Cr of depreciation (the yearly wear and tear on existing assets). So it is spending about what it takes to replace what wears out, or less. Work still in progress is ₹74.0 Cr (FY26): assets paid for that are not earning yet. In short: neither the daily cycle nor new spending is soaking up the cash, so the picture is fairly clean. ## What is J B Chemicals & Pharmaceuticals' P/E ratio, and how does it compare with its own history? J B Chemicals & Pharmaceuticals Ltd's P/E is 53.3×, about the highest it has ever been. Its usual P/E (the middle reading) is 27.6×, over 10 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. Why this happened. JB Pharma's debt-free status since debt repayment enables treasury income that compounds PAT growth. Other income grew from Rs 8 Cr to Rs 18 Cr YoY in Q3 FY26 purely from surplus cash deployment. With net cash at Rs 1,200 Cr post-Q4, this ~Rs 70-80 Cr annualized contribution is a structural PAT support. The Rs 9.3/share dividend recommendation signals continued return discipline. Why the multiple is where it is: over the past year earnings per share moved +4.3% while the price moved +45.6%. The price did better than earnings, which pushed the multiple up within its own range. Where the price move came from: over 5 years the price moved +20.6% a year; about +9.1% a year came from earnings growth and about +11.5 percentage points from the multiple (the market paying more); over 10 years the price moved +33.8% a year; about +23.2% a year came from earnings growth and about +10.6 percentage points from the multiple (the market paying more). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: the multiple is high against its own past, so the earnings trend underneath matters more than the multiple. ## What growth does the J B Chemicals & Pharmaceuticals share price assume? Worked out from its price on 13 June 2026, J B Chemicals & Pharmaceuticals Ltd's share price assumed profit growth of about 25.8% a year. Over the past 10 years its profit actually grew 15.8% a year. Today its P/E is 53.3×, higher than 98% of its own last 10 years. This is a one-day reading, taken on 13 June 2026. Every other number on this page, the multiple included, uses the latest price as of 16 July 2026. A higher price assumes more growth and a lower price less, so it changes whenever the price changes, and this page does not update it between measurements. ## Is the J B Chemicals & Pharmaceuticals business getting better or worse? J B Chemicals & Pharmaceuticals Ltd's business is growing steadily. Revenue, profit and EPS growth have stayed positive throughout, and ROCE is steady at 23.9% (four quarters to Mar 2026). This is based on 12 quarters of 4 measures. Why it matters: steady growth with healthy returns is how a business compounds over time. ## What is the J B Chemicals & Pharmaceuticals story, and has it been checked? J B Chemicals & Pharmaceuticals Ltd's story is not scored yet against the checks our research set on 17 May 2026. Where it sits in its own cycle: fully expanded. Our read, 17 May 2026. A chronic-mix compounder hit by a Torrent-integration reset, the branded core is intact, but CDMO missed by 12-14pp and management guidance credibility is impaired. From the numbers. FII stake-cutting since Dec 2024 peak of 14.64%. Cycle segment is FULLY EXPANDED… From the price. Price stage 2, week 34, above its 200-day line, relative strength rising. What is not proven yet. 4 clear guidance misses across 4 calls: CDMO (flat vs 12-14%), domestic (9% vs 12-14%), international (Q4 -9% vs high-single H2 guide), CDMO FY27 run rate abandoned. Risks remain undisclosed until post-fact. The test written in advance. Management Guidance Credibility, Systematic Pattern of Misses. Measured by: Management Guidance Credibility, Systematic Pattern of Misses Q1 FY27, does India branded return to double-digit as guided? Does CDMO show positive momentum? by the next result. The test written in advance. The test written in advance. Trade Generics Exit Depresses Reported Growth 3+ Quarters. Measured by: Trade Generics Exit Depresses Reported Growth 3+ Quarters Organic branded India growth (ex-trade generics), must track separately from reported topline by the next result. What the company does. India branded grew 11% vs 10% IPM in FY26; chronic segment +19% vs industry +14%; 400bps gross margin expansion in Q4 to 70% from trade-generics exit, the underlying franchise is healthy. CDMO finished FY26 flat at Rs 494 Cr vs explicit 12-14% growth guidance held across two prior calls; execution delays surfaced for the first time post-acquisition, the highest-multiple segment has now missed guidance 3 consecutive times in 4 calls. FII stake-cutting;. Lever 2 · Value-added mix: building. Chronic segment grew 19% vs industry 14% in FY26; trade-generics exit (7-8% of India sales) drove 400bps gross margin expansion to 70% in Q4, structural improvement, not seasonal. What proves it keeps working: Chronic Portfolio Mix Shift, Structural Gross Margin Expansion. It stops working if Q1 FY27, does India branded return to double-digit as guided? Does CDMO show positive momentum? Lever 15 · Market-share gains: building. Fastest growing among top-25 IPM companies; 300-400bps volume growth advantage; 6 brands now in top-300 IPM. What proves it keeps working: India Market Share Gains, Outperforming IPM Consistently. Lever 5 · Regulatory approval: building. Procurement synergies visible since April 2026; distribution network optimization underway; back-end consolidation and coverage expansion for chronic therapies expected post-merger completion. What proves it keeps working: Torrent Merger Integration Synergies. Lever 3 · Management change: building. CDMO flat at Rs 494 Cr in FY26 vs 12-14% guide; management confirms customers and capacity are adequate, execution acceleration is the only constraint. What proves it keeps working: CDMO Business Recovery (Execution-Dependent). Sources: our stock research file (17 May 2026) · quarterly results through Mar 2026 · the company’s own earnings calls. The story check is re-scored every results season; the record below never changes. ## Did J B Chemicals & Pharmaceuticals management deliver what it promised? What J B Chemicals & Pharmaceuticals Ltd's management promised, against what actually happened: 4 promises on the record. Read straight from the company’s own earnings calls. A promise that slipped stays on this page after it is met. CDMO FY26 Annual Growth Guidance Missed · 12 May 2026. Both prior calls maintained explicit 12-14% FY26 CDMO growth guidance, with the Nov 2025 call additionally affirming a strong H2 FY26 order book and robust pipeline. The May 2026 call reveals CDMO finished the full year flat at 494 crores, approximately 12-14 percentage points below the guided growth rate. Execution delays in product delivery are now surfaced for the first time as a structural challenge, a risk that went entirely unmentioned in both prior calls. India Domestic FY26 Growth Guidance Missed · 12 May 2026. Both prior calls maintained explicit 12-14% domestic business growth guidance for FY26, with the Nov 2025 management reaffirming it directly in response to an analyst question. The May 2026 call reports full-year India business growth of only 9% overall and 11% for branded, attributing the shortfall to trade generics rationalization - a business line contributing 7-8% of India revenue that was never flagged as a risk to the 12-14% guidance in either prior call. International Formulations H2 FY26 Recovery Guidance Contradicted · 12 May 2026. The Nov 2025 call explicitly guided for high single-digit H2 FY26 growth in ROW markets and a South Africa bounce-back, citing a strong order book. Instead, Q4 FY26 international formulations declined 9% and full-year growth was only 2%. The May 2026 call attributes the Q4 decline to an operational reset under Torrent and container shipping disruptions - factors entirely absent from the Nov 2025 recovery narrative. CDMO FY27 Quarterly Run Rate Goal Not Reaffirmed and Execution Delays Newly Surfaced · 12 May 2026. The Jul 2025 call committed to a specific FY27 quarterly CDMO run rate of INR140-150 crore, implying roughly 13-21% growth from the now-flat FY26 base, and Nov 2025 closing remarks continued to support mid-teens CDMO growth going forward. The May 2026 call, the first post-acquisition opportunity to address FY27 CDMO outlook, provides only vague positive momentum language and newly surfaces structural execution delays, without acknowledging or updating the prior specific quarterly run rate goal. Every quote above is taken word for word from the company’s own earnings calls. ## What is J B Chemicals & Pharmaceuticals management's track record? J B Chemicals & Pharmaceuticals (JB Pharma) demonstrates a robust track record of meeting or exceeding management guidance. For FY25, the company delivered 12% revenue growth (₹3,918 crore) and 14% domestic formulation growth, hitting the upper end of its 12-14% guidance. Despite a temporary slowdown in the CDMO segment during H1 FY25, management's guidance for a H2 recovery was validated by an 18.3% on a year earlier bounce in January to March 2025. In FY26, the company has maintained its guided operating margin corridor of 27-29%, reporting 28.7% in October to December 2025. ### Regulatory and governance record J B Chemicals & Pharmaceuticals Ltd (JBCHEPHARM) is largely clean of major regulatory red flags, with no active SEBI bans, CBI investigations, or fraud chargesheets found as of April 2026. The most significant recent regulatory event is a GST penalty of ₹80.81 lakh (not ₹80.81 crore as misreported by some aggregators) issued by the State Tax Officer, Chennai, on March 18, 2026. This penalty, under Section 74 of the GST Act, relates to tax liability differences for FY 2019-20. The company is appealing the order and expects no material financial impact. Additionally, the company processed a promoter reclassification request for Tau Investment Holdings Pte. Ltd in January 2026 and saw the resignation of three senior executives in March 2026, which appear to be routine corporate transitions. (Checked 20 April 2026.) ## How much does J B Chemicals & Pharmaceuticals earn on its capital? J B Chemicals & Pharmaceuticals Ltd earned a ROCE of 25% in FY26. That is up from a low of 11% in FY18. Its return on capital used (ROIC) is 10.2 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 17.1% net margin and 0.84× asset turnover (sales divided by assets). Why the return is what it is (FY26): a 17.1% net margin × 0.84× asset turnover × 1.19× leverage (assets divided by equity) ≈ 17.1% on equity. The margin does most of the work; borrowing plays a small part, so this return is earned, not borrowed. The key test, return on capital used minus the cost of capital: 22.2% − 12.0% = +10.2 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. A gap this wide means each rupee put back into the business creates more than a rupee of value. ## Does J B Chemicals & Pharmaceuticals have too much debt? J B Chemicals & Pharmaceuticals Ltd has total debt of ₹4.0 Cr against shareholder equity of ₹4,159 Cr as of Mar 2026, so its debt is 0.00× its equity, which is very little. Year by year, that ratio went from 0.03 in FY22 to 0.00 in FY26. So the returns on this page come from the business, not from borrowed money. ## What is the J B Chemicals & Pharmaceuticals shareholding pattern? Promoters cut their stake in J B Chemicals & Pharmaceuticals Ltd by 5.0 percentage points over 8 quarters, the biggest change among its owners. Promoters now own 48.8% of the company. Foreign institutions moved +4.2 points over the same period, to 16.3%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. Why this happened. CDMO has top-5 originator customers (P&G, Kenvue, Abnova, Reckitt, unnamed fifth) with signed contracts in place. The execution bottleneck is in process development capability, management stated under analyst pressure that 'customers and capacities are present; it is just execution that needs to be addressed.' FY27 goal of Rs 140-150 Cr quarterly (guided July 2025) was abandoned without update, but management expressed confidence in positive momentum on a 12-month basis. If execution genuinely improves (team expansion, faster delivery), CDMO could accelerate from the flat FY26 base. Not underwritten until Q1 FY27 actuals show recovery. Over the last two years: Promoters: −5.0 points over 8 quarters, to 48.8%; Foreign institutions: +4.2 points over 8 quarters, to 16.3%; Domestic institutions: +3.8 points over 8 quarters, to 21.4%. Why the owners changed: promoters drove it (−5.0 points), with the other side taken by foreign institutions (+4.2 points). They reduced their stake. ## How far is J B Chemicals & Pharmaceuticals from balance-sheet trouble? For J B Chemicals & Pharmaceuticals Ltd, the Z-score is 23.55. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is well clear of danger. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why this happened. Torrent acquired KKR's 46.39% stake for Rs 11,917 Cr (closed January 21, 2026), with merger hearing scheduled second week June 2026 and completion expected 1-2 months thereafter. Synergy levers: (1) procurement advantages visible since April, (2) distribution network optimization, (3) back-end function consolidation, (4) field force coverage expansion for JB's chronic brands through Torrent's larger network. Revenue synergies require merger completion before they materialize. Rs 400-450 Cr total synergy estimate over 2-3 years per Torrent's Q3 FY26 commentary. Why it matters: a Z-score of 23.55 is well clear of the danger zone, so the balance sheet is not the risk here. ## How does J B Chemicals & Pharmaceuticals rank in its industry? 45.8 out of 100, rank 29 of 44 in Pharma - Formulators, with 59% of the evidence available. J B Chemicals & Pharmaceuticals Ltd scores 45.8 out of 100 against the 44 companies it is compared with in Pharma - Formulators, ranking 29. Some evidence is missing, so the score is pulled toward the middle on purpose. The three scored parts add up to the total exactly: 16.4 + 22.1 + 7.3 = 45.8 (no relative-strength reading this week; its 20 points are shared across the other three). This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is J B Chemicals & Pharmaceuticals compared with? J B Chemicals & Pharmaceuticals ranks 29 of 44 Pharma - Formulators companies on the 4-Factor Sector Score, with 45.8 out of 100. 1. [Marksans Pharma Ltd](https://www.sectoralpha.in/stocks/marksans-pharma-ltd) MARKSANS · losing its lead · Most evidence points up · 78% evidence 75.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 30.5/35 · Revenue 24.2% · Profit 60.3% · Operating margin change 3 points · 100% evidence Capital efficiency 18.0/25 · ROCE 18.8% (year to Mar 2026) · Operating margin 22.8% · 100% evidence Valuation 15.4/20 · P/E 23.8× · PEG 0.92 · 65% evidence Relative strength 11.9/20 · Strength vs its industry (price vs its 52-week average, weekly) n/a · Strength vs NIFTY 500 (same reading) 31.3% · 1 year 53.6% · 25% evidence · 11 of 12 weeks ahead Exact sum: 30.5 + 18 + 15.4 + 11.9 = 75.8 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 2. [Emcure Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/emcure-pharmaceuticals-ltd) EMCURE · leader · Most evidence points up · 75% evidence 72.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 26.1/35 · Revenue 21.1% · Profit 33.3% · Operating margin change 0 points · 95% evidence Capital efficiency 18.0/25 · ROCE 24% (year to Mar 2026) · Operating margin 20.9% · 76% evidence Valuation 10.0/20 · P/E 40.5× · PEG n/a · 15% evidence Relative strength 18.7/20 · Strength vs its industry (price vs its 52-week average, weekly) 17.5% · Strength vs NIFTY 500 (same reading) 33.7% · 1 year 72.4% · 100% evidence · 10 of 12 weeks ahead Exact sum: 26.1 + 18 + 10 + 18.7 = 72.8 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 3. [Kwality Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/kwality-pharmaceuticals-ltd) KPL · breaking out · Most evidence points up · 75% evidence 68.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 32.5/35 · Revenue 47.6% · Profit 95.9% · Operating margin change 4 points · 100% evidence Capital efficiency 17.0/25 · ROCE 24.1% (year to Mar 2026) · Operating margin 27.6% · 100% evidence Valuation 6.5/20 · P/E 45.5× · PEG n/a · 50% evidence Relative strength 12.3/20 · Strength vs its industry (price vs its 52-week average, weekly) n/a · Strength vs NIFTY 500 (same reading) 68.2% · 1 year 345.7% · 25% evidence · 9 of 9 weeks ahead Exact sum: 32.5 + 17 + 6.5 + 12.3 = 68.3 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 4. [Rubicon Research Ltd](https://www.sectoralpha.in/stocks/rubicon-research-ltd) RUBICON · losing its lead · Most evidence points up · 87% evidence 67.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.0/35 · Revenue 46.3% · Profit 90.1% · Operating margin change 2 points · 100% evidence Capital efficiency 18.8/25 · ROCE 28.4% (year to Mar 2026) · Operating margin 25% · 100% evidence Valuation 8.1/20 · P/E 84.3× · PEG 2.11 · 65% evidence Relative strength 16.5/20 · Strength vs its industry (price vs its 52-week average, weekly) 28.5% · Strength vs NIFTY 500 (same reading) 42.3% · 1 year 144.6% · 70% evidence · 10 of 12 weeks ahead Exact sum: 24 + 18.8 + 8.1 + 16.5 = 67.4 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 5. [Accent Microcell Ltd](https://www.sectoralpha.in/stocks/accent-microcell-ltd) ACCENTMIC · losing its lead · Most evidence points up · 65% evidence 66.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.8/35 · Revenue n/a · Profit n/a · Operating margin change 7 points · 27% evidence Capital efficiency 21.6/25 · ROCE 24.9% (year to Mar 2026) · Operating margin 23.4% · 100% evidence Valuation 10.1/20 · P/E 25.6× · PEG n/a · 50% evidence Relative strength 12.7/20 · Strength vs its industry (price vs its 52-week average, weekly) 13.6% · Strength vs NIFTY 500 (same reading) 27.2% · 1 year 97.1% · 100% evidence · 11 of 12 weeks ahead Exact sum: 21.8 + 21.6 + 10.1 + 12.7 = 66.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [Ajanta Pharma Ltd](https://www.sectoralpha.in/stocks/ajanta-pharma-ltd) AJANTPHARM · quiet · Most evidence points up · 100% evidence 65.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 30.3/35 · Revenue 25% · Profit 29.8% · Operating margin change 7 points · 100% evidence Capital efficiency 21.1/25 · ROCE 34.5% (year to Mar 2026) · Operating margin 30.6% · 100% evidence Valuation 9.2/20 · P/E 32.4× · PEG 1.91 · 100% evidence Relative strength 5.1/20 · Strength vs its industry (price vs its 52-week average, weekly) -10.2% · Strength vs NIFTY 500 (same reading) 2.4% · 1 year 31.7% · 100% evidence · 8 of 12 weeks ahead Exact sum: 30.3 + 21.1 + 9.2 + 5.1 = 65.7 · What this means: Earnings are strong; relative strength in its sector is -10.2% and the one-year return is 31.7%. 7. [Mankind Pharma Ltd](https://www.sectoralpha.in/stocks/mankind-pharma-ltd) MANKIND · turning · Most evidence points up · 100% evidence 65.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 26.3/35 · Revenue 13.5% · Profit 27.5% · Operating margin change 2 points · 100% evidence Capital efficiency 15.8/25 · ROCE 13.5% (year to Mar 2026) · Operating margin 27% · 100% evidence Valuation 10.4/20 · P/E 48.3× · PEG 2.64 · 100% evidence Relative strength 12.8/20 · Strength vs its industry (price vs its 52-week average, weekly) -3.4% · Strength vs NIFTY 500 (same reading) 10.8% · 1 year 17.1% · 100% evidence · 4 of 12 weeks ahead Exact sum: 26.3 + 15.8 + 10.4 + 12.8 = 65.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 8. [Bliss GVS Pharma Ltd](https://www.sectoralpha.in/stocks/bliss-gvs-pharma-ltd) BLISSGVS · leader · Most evidence points up · 82% evidence 65.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 30.2/35 · Revenue 25% · Profit 43.1% · Operating margin change 8 points · 95% evidence Capital efficiency 14.5/25 · ROCE 16.9% (year to Mar 2026) · Operating margin 25.9% · 76% evidence Valuation 6.5/20 · P/E 44.8× · PEG n/a · 50% evidence Relative strength 14.1/20 · Strength vs its industry (price vs its 52-week average, weekly) 55.9% · Strength vs NIFTY 500 (same reading) 69.5% · 1 year 325.8% · 100% evidence · 12 of 12 weeks ahead Exact sum: 30.2 + 14.5 + 6.5 + 14.1 = 65.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 9. [Alembic Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/alembic-pharmaceuticals-ltd) APLLTD · leader · Evidence leans up · 85% evidence 64.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 25.8/35 · Revenue 19.7% · Profit 32.7% · Operating margin change 5 points · 100% evidence Capital efficiency 12.1/25 · ROCE 12.6% (year to Mar 2026) · Operating margin 21.6% · 100% evidence Valuation 14.5/20 · P/E 24.3× · PEG 1.28 · 100% evidence Relative strength 11.6/20 · Strength vs its industry (price vs its 52-week average, weekly) n/a · Strength vs NIFTY 500 (same reading) 24.7% · 1 year 15.9% · 25% evidence · 9 of 12 weeks ahead Exact sum: 25.8 + 12.1 + 14.5 + 11.6 = 64 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 10. [Ipca Laboratories Ltd](https://www.sectoralpha.in/stocks/ipca-laboratories-ltd) IPCALAB · leader · Evidence leans up · 82% evidence 62.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.5/35 · Revenue 12% · Profit 73.8% · Operating margin change 2 points · 95% evidence Capital efficiency 15.7/25 · ROCE 17% (year to Mar 2026) · Operating margin 23.1% · 76% evidence Valuation 11.7/20 · P/E 33.5× · PEG n/a · 50% evidence Relative strength 10.5/20 · Strength vs its industry (price vs its 52-week average, weekly) -3.6% · Strength vs NIFTY 500 (same reading) 9.9% · 1 year 28.4% · 100% evidence · 11 of 12 weeks ahead Exact sum: 24.5 + 15.7 + 11.7 + 10.5 = 62.4 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 11. [Fredun Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/fredun-pharmaceuticals-ltd) FREDUN · losing its lead · Evidence leans up · 70% evidence 61.2 out of 100 Growth Capital Valuation Relative 12. [FDC Ltd](https://www.sectoralpha.in/stocks/fdc-ltd) FDC · turning · Evidence leans up · 75% evidence 59.2 out of 100 Growth Capital Valuation Relative 13. [Aurobindo Pharma Ltd](https://www.sectoralpha.in/stocks/aurobindo-pharma-ltd) AUROPHARMA · leader · Evidence leans up · 100% evidence 58.9 out of 100 Growth Capital Valuation Relative 14. [Corona Remedies Ltd](https://www.sectoralpha.in/stocks/corona-remedies-ltd) CORONA · breaking out · Evidence leans up · 73% evidence 58.3 out of 100 Growth Capital Valuation Relative 15. [Lupin Ltd](https://www.sectoralpha.in/stocks/lupin-ltd) LUPIN · quiet · Evidence leans up · 90% evidence 57.2 out of 100 Growth Capital Valuation Relative 16. [Gufic BioSciences Ltd](https://www.sectoralpha.in/stocks/gufic-biosciences-ltd) GUFICBIO · leader · Evidence leans up · 75% evidence 56.8 out of 100 Growth Capital Valuation Relative 17. [ERIS Lifesciences Ltd](https://www.sectoralpha.in/stocks/eris-lifesciences-ltd) ERIS · basing · Evidence leans up · 67% evidence 56.0 out of 100 Growth Capital Valuation Relative 18. [Kilitch Drugs (India) Ltd](https://www.sectoralpha.in/stocks/kilitch-drugs-indialtd) KILITCH · turning · Evidence leans up · 82% evidence 55.8 out of 100 Growth Capital Valuation Relative 19. [Caplin Point Laboratories Ltd](https://www.sectoralpha.in/stocks/caplin-point-laboratories-ltd) CAPLIPOINT · quiet · Evidence leans up · 90% evidence 55.2 out of 100 Growth Capital Valuation Relative 20. [Wockhardt Ltd](https://www.sectoralpha.in/stocks/wockhardt-ltd) WOCKPHARMA · losing its lead · Evidence leans up · 83% evidence 54.7 out of 100 Growth Capital Valuation Relative 21. [Influx Healthtech Ltd](https://www.sectoralpha.in/stocks/influx-healthtech-ltd) INFLUX · quiet · Evidence leans up · 63% evidence 54.3 out of 100 Growth Capital Valuation Relative 22. [Amrutanjan Health Care Ltd](https://www.sectoralpha.in/stocks/amrutanjan-health-care-ltd) AMRUTANJAN · breaking out · Evidence leans up · 90% evidence 54.1 out of 100 Growth Capital Valuation Relative 23. [Akums Drugs & Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/akums-drugs-pharmaceuticals-ltd) AKUMS · losing its lead · Evidence leans up · 75% evidence 53.3 out of 100 Growth Capital Valuation Relative 24. [Strides Pharma Science Ltd](https://www.sectoralpha.in/stocks/strides-pharma-science-ltd) STAR · breaking out · Evidence leans up · 82% evidence 52.3 out of 100 Growth Capital Valuation Relative 25. [Zydus Lifesciences Ltd](https://www.sectoralpha.in/stocks/zydus-lifesciences-ltd) ZYDUSLIFE · breaking out · Evidence leans up · 90% evidence 51.5 out of 100 Growth Capital Valuation Relative 26. [Glenmark Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/glenmark-pharmaceuticals-ltd) GLENMARK · breaking out · Evidence leans up · 90% evidence 50.6 out of 100 Growth Capital Valuation Relative 27. [Bafna Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/bafna-pharmaceuticals-ltd) BAFNAPH · breaking out · Evidence leans down · 68% evidence 49.1 out of 100 Growth Capital Valuation Relative 28. [Alkem Laboratories Ltd](https://www.sectoralpha.in/stocks/alkem-laboratories-ltd) ALKEM · quiet · Evidence leans down · 82% evidence 48.3 out of 100 Growth Capital Valuation Relative 29. J B Chemicals & Pharmaceuticals Ltd this page JBCHEPHARM · Too little evidence to rank firmly · 59% evidence 45.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 16.4/43.75 · Revenue 5.9% · Profit 7.4% · Operating margin change -2 points · 56% evidence Capital efficiency 22.1/31.25 · ROCE 25.4% (year to Mar 2026) · Operating margin 22.2% · 75% evidence Valuation 7.3/25 · P/E 53.3× · PEG 1.98 · 100% evidence Relative strength: no reading this week · its 20 points are shared across the other three Exact sum: 16.4 + 22.1 + 7.3 = 45.8 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. 30. [Bharat Parenterals Ltd](https://www.sectoralpha.in/stocks/bharat-parenterals-ltd) BPLPHARMA · breaking out · Too little evidence to rank firmly · 52% evidence 45.8 out of 100 Growth Capital Valuation Relative 31. [Zim Laboratories Ltd](https://www.sectoralpha.in/stocks/zim-laboratories-ltd) ZIMLAB · leader · Evidence leans down · 74% evidence 42.8 out of 100 Growth Capital Valuation Relative 32. [Bajaj Healthcare Ltd](https://www.sectoralpha.in/stocks/bajaj-healthcare-ltd) BAJAJHCARE · basing · Evidence leans down · 90% evidence 42.7 out of 100 Growth Capital Valuation Relative 33. [Lincoln Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/lincoln-pharmaceuticals-ltd) LINCOLN · quiet · Evidence leans down · 90% evidence 41.5 out of 100 Growth Capital Valuation Relative 34. [Sun Pharmaceutical Industries Ltd](https://www.sectoralpha.in/stocks/sun-pharmaceutical-industries-ltd) SUNPHARMA · quiet · Evidence leans down · 100% evidence 39.8 out of 100 Growth Capital Valuation Relative 35. [RPG Life Sciences Ltd](https://www.sectoralpha.in/stocks/rpg-life-sciences-ltd) RPGLIFE · losing its lead · Evidence leans down · 90% evidence 38.9 out of 100 Growth Capital Valuation Relative 36. [Indoco Remedies Ltd](https://www.sectoralpha.in/stocks/indoco-remedies-ltd) INDOCO · turning · Too little evidence to rank firmly · 52% evidence 37.8 out of 100 Growth Capital Valuation Relative 37. [Suven Life Sciences Ltd](https://www.sectoralpha.in/stocks/suven-life-sciences-ltd) SUVEN · quiet · Most evidence points down · 67% evidence 34.4 out of 100 Growth Capital Valuation Relative 38. [Torrent Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/torrent-pharmaceuticals-ltd) TORNTPHARM · quiet · Most evidence points down · 100% evidence 34.2 out of 100 Growth Capital Valuation Relative 39. [Natco Pharma Ltd](https://www.sectoralpha.in/stocks/natco-pharma-ltd) NATCOPHARM · quiet · Most evidence points down · 90% evidence 31.9 out of 100 Growth Capital Valuation Relative 40. [Dr Reddys Laboratories Ltd](https://www.sectoralpha.in/stocks/dr-reddys-laboratories-ltd) DRREDDY · breaking out · Most evidence points down · 100% evidence 30.4 out of 100 Growth Capital Valuation Relative 41. [Cipla Ltd](https://www.sectoralpha.in/stocks/cipla-ltd) CIPLA · quiet · Most evidence points down · 100% evidence 27.9 out of 100 Growth Capital Valuation Relative 42. [Biocon Ltd](https://www.sectoralpha.in/stocks/biocon-ltd) BIOCON · basing · Most evidence points down · 100% evidence 22.7 out of 100 Growth Capital Valuation Relative 43. [Syncom Healthcare Ltd](https://www.sectoralpha.in/stocks/syncom-healthcare-ltd) SYNCOM · Too little evidence to rank firmly · 17% evidence 42.4 out of 100 Growth Capital Valuation Relative 44. [Sai Parenterals Ltd](https://www.sectoralpha.in/stocks/sai-parenterals-ltd) SAIPARENT · quiet · Too little evidence to rank firmly · 36% evidence 38.3 out of 100 Growth Capital Valuation Relative Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. In this ranking every company's P/E uses its own latest official close and its last four filed quarters, the same rule as the top of this page. ROCE here is each company's last full year, as labelled, so it can differ from the four-quarter ROCE above. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Pharma - Formulators](https://www.sectoralpha.in/sectors/pharma-formulators), all 44 compared on one page. ## Which companies are close to J B Chemicals & Pharmaceuticals in size? J B Chemicals & Pharmaceuticals is the 15th largest of 44 Pharma - Formulators companies on Sector Alpha by market value (at the 18 November 2026 close). Just above it: Ipca Laboratories, Emcure Pharmaceuticals and Ajanta Pharma. Just below it: Wockhardt, Rubicon Research and Alembic Pharmaceuticals. ### Pharma - Formulators companies close in size 1. [Ipca Laboratories Ltd](https://www.sectoralpha.in/stocks/ipca-laboratories-ltd) ₹47,039 crore 2. [Emcure Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/emcure-pharmaceuticals-ltd) ₹44,294 crore 3. [Ajanta Pharma Ltd](https://www.sectoralpha.in/stocks/ajanta-pharma-ltd) ₹40,910 crore 4. J B Chemicals & Pharmaceuticals Ltd ₹38,677 crore 5. [Wockhardt Ltd](https://www.sectoralpha.in/stocks/wockhardt-ltd) ₹32,934 crore 6. [Rubicon Research Ltd](https://www.sectoralpha.in/stocks/rubicon-research-ltd) ₹27,451 crore 7. [Alembic Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/alembic-pharmaceuticals-ltd) ₹20,528 crore [All 44 Pharma - Formulators companies, largest first](https://www.sectoralpha.in/sectors/pharma-formulators#all-companies) ### Companies close in size in other industries 1. [Anand Rathi Wealth Ltd](https://www.sectoralpha.in/stocks/anand-rathi-wealth-ltd) ₹39,437 crore · Finance - Capital Markets - Wealth Management 2. [Rail Vikas Nigam Ltd](https://www.sectoralpha.in/stocks/rail-vikas-nigam-ltd) ₹39,407 crore · Infra - Construction & Contracting 3. J B Chemicals & Pharmaceuticals Ltd ₹38,677 crore 4. [Narayana Hrudayalaya Ltd](https://www.sectoralpha.in/stocks/narayana-hrudayalaya-ltd) ₹38,650 crore · Hospitals 5. [Global Health Ltd](https://www.sectoralpha.in/stocks/global-health-ltd) ₹38,627 crore · Hospitals ## What else do people ask about J B Chemicals & Pharmaceuticals? ### What were J B Chemicals & Pharmaceuticals's latest quarterly results? J B Chemicals & Pharmaceuticals Ltd reported revenue of ₹904 Cr and net profit of ₹101 Cr for the Mar 2026 quarter. Revenue fell 4.7% and profit fell 30.8% compared with a year earlier. Earnings per share were ₹6.31 (as of 16 July 2026). ### What is J B Chemicals & Pharmaceuticals's market cap? J B Chemicals & Pharmaceuticals Ltd's market capitalisation is ₹38,677 Cr at a share price of ₹2,408.90. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 16 July 2026). ### How is J B Chemicals & Pharmaceuticals performing? J B Chemicals & Pharmaceuticals Ltd's share price has been rising for 34 weeks. In its latest quarter, revenue fell 4.7% and profit fell 30.8% compared with a year earlier. Over the past 13 weeks it has done better than the NIFTY 500, for 9 weeks running (as of 16 July 2026). ### Will J B Chemicals & Pharmaceuticals's share price go up? This page does not forecast J B Chemicals & Pharmaceuticals Ltd's share price. What it shows instead: the share price is ₹2,408.90, and it has been rising for 34 weeks. Its P/E of 53.3× is higher than 98% of its own last 10 years (as of 16 July 2026). ### Where is J B Chemicals & Pharmaceuticals in its business cycle? J B Chemicals & Pharmaceuticals Ltd's FY26 operating margin was 26.7%, against a 13-year range of 14.5% to 27.4%. The latest quarter was 22.2%, the middle of its own range, neither a peak nor a low. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 16 July 2026). ### What could break the J B Chemicals & Pharmaceuticals story? The main question: the share price moved +45.6% in a year while yearly earnings per share moved +4.3%. The difference came from the market paying a higher multiple. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 16 July 2026). ### Is J B Chemicals & Pharmaceuticals a stock worth studying right now? What the numbers show: J B Chemicals & Pharmaceuticals Ltd's share price has risen faster than its earnings: +45.6% in a year, against +4.3% for earnings per share. The main open question: whether earnings grow into a price that has already moved. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 16 July 2026). ### Is there a J B Chemicals & Pharmaceuticals share price forecast for 2026? What management itself guided: India branded business return to double-digit or low-teens growth within couple of quarters. What is changing at J B Chemicals & Pharmaceuticals, from the latest results and calls: chronic portfolio mix shift, structural gross margin expansion, india market share gains, outperforming ipm consistently and torrent merger integration synergies. What would change the story: 4 clear guidance misses across 4 calls: CDMO (flat vs 12-14%), domestic (9% vs 12-14%), international (Q4 -9% vs high-single H2 guide), CDMO FY27 run rate abandoned. Risks remain undisclosed until post-fact. ### Where does this page get J B Chemicals & Pharmaceuticals' management information? From J B Chemicals & Pharmaceuticals' results calls, its filings and public records on governance, each dated on the page. Management’s plans are shown as plans, never as results. ## Lists - Small & mid cap stocks: https://www.sectoralpha.in/small-cap-stocks-india - Pharma stocks: https://www.sectoralpha.in/sectors/pharma-stocks-india This is research, not advice. We’re not SEBI-registered.